Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name	of entity	
Nov	ogen Limited ("Novogen")	
	063 259 754 (the entity) give ASX the following info	rmation
Pai	rt 1 - All issues nust complete the relevant sections (attach sheets	
1	⁺ Class of ⁺ securities issued or to be issued	Ordinary fully paid share (Share)
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	413,794 fully-paid Shares
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully-paid ordinary voting shares Ranks pari passu with all existing Shares

⁺ See chapter 19 for defined terms.

4	respects from the date of allotment with an existing +class of quoted +securities?	with all existing Ordinary Shares.
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	Issue price per Share: \$0.145
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The Shares referred to in Item 2 are issued pursuant to a conversion notice received under the Convertible Securities Agreement announced to the market on 4 July 2013.
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of +securities issued without security holder approval under rule 7.1	413,794 fully-paid Shares

Appendix 3B Page 2 1/1/2003

⁺ See chapter 19 for defined terms.

6d	Number of +securities issued with security holder approval under rule 7.1A	N/A
бе	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of +securities issued under an exception in rule 7.2	N/A
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6I	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A
7	+Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	8 October 2013

⁺ See chapter 19 for defined terms.

		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the securities in clause 2 if applicable)	144,622,257	Ordinary Shares
			. I
		Number	+Class
9	Number and *class of all *securities not quoted on ASX (<i>including</i> the securities in clause 2 if applicable)	6,007,216	Unlisted options with various exercise dates and prices.
		1	Unlisted convertible note with a face value of \$280,000
		60,000,000	Unlisted convertible notes, with aggregate face values of \$1,500,000
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part	2 - Bonus issue or pro	rata issue	
11	Is security holder approval required?		
10	To the feet of the second second		
12	Is the issue renounceable or non-renounceable?		
13	Ratio in which the *securities will be offered		
14	⁺ Class of ⁺ securities to which the offer relates		
	oner relates		
15	⁺ Record date to determine entitlements		
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?		
17	Deliev for deciding antidement		
17	Policy for deciding entitlements in relation to fractions		

Appendix 3B Page 4 1/1/2003

⁺ See chapter 19 for defined terms.

18	Names of countries in which the entity has *security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations
20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders
25	If the issue is contingent on +security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do *security holders sell their entitlements in full through a

⁺ See chapter 19 for defined terms.

Appendix 3B

New issue announcement

	broker?	
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	
33	⁺ Despatch date	
	3 - Quotation of secur	
34	Type of securities (tick one)	
(a)	Securities described in Part 1	
(b)		of the escrowed period, partly paid securities that become fully paid, employee nds, securities issued on expiry or conversion of convertible securities

Appendix 3B Page 6 1/1/2003

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to docum	o indicate you are providing the inform ents	ation or	
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36		1,001 - 5,000 5,001 - 10,000 10,001 - 100,000	
37	A copy of any trust deed for	the additional ⁺ securities	
Enti	ties that have ticked box 34((b)	
38	Number of securities for whice +quotation is sought	h	
39	Class of *securities for whic quotation is sought	h	
40	Do the *securities rank equally in a respects from the date of allotmer with an existing *class of quote *securities?	nt	
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which the participate for the next dividence (in the case of a trust distribution) or interest payment • the extent to which they do not rank equally, other than it relation to the next dividence distribution or interest payment	y I, t, ot n	

⁺ See chapter 19 for defined terms.

Appendix 3B

New issue announcement

41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
			L
		Number	+Class
42	Number and *class of all *securities		
	quoted on ASX (including the		
	securities in clause 38)		

Appendix 3B Page 8 1/1/2003

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Company secretary)	Date: 8 October 2013
Print name:	Andrew Bursill	
	== == == ==	

⁺ See chapter 19 for defined terms.

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	103,805,676	
Add the following:		
Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2	34,470,357	
Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval	34,470,337	
Number of partly paid +ordinary securities that became fully paid in that 12 month period		
Note:		
Include only ordinary securities here – other classes of equity securities cannot be added		
• Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed		
It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	-	
"A"	138,276,033	

Appendix 3B Page 10 1/1/2003

⁺ See chapter 19 for defined terms.

Γ		
Step 2: Calculate 15% of "A"		
"B"	0.15	
Multiply "A" by 0.15	20,741,404	
Step 3: Calculate "C", the amount of has already been used	placement capacity under rule 7.1 that	
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:		
Under an exception in rule 7.2	10,346,224	
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
Note:		
This applies to equity securities, unless specifically excluded – not just ordinary securities		
Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed		
It may be useful to set out issues of securities on different dates as separate line items		
"C"	10,346,224	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	20,741,404	
Note: number must be same as shown in Step 2		
Subtract "C"	10,346,224	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	10,395,180	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	N/A	
Multiply "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of phas already been used	placement capacity under rule 7.1A that	
Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A	
Notes:		
• This applies to equity securities – not just ordinary securities		
• Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed		
• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained		
• It may be useful to set out issues of securities on different dates as separate line items		
"E"	N/A	

Appendix 3B Page 12 1/1/2003

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	N/A
Note: number must be same as shown in Step 2	
Subtract "E"	N/A
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.